Download PDF
Thromb Haemost 2004; 92(02): 425-426
DOI: 10.1055/s-0037-1613731
Letters to the Editor
Schattauer GmbH

Acute myocardial infarction during substitution with recombinant factor VIII concentrate in a patient with mild haemophilia A

Jean-Louis Kerkhoffs
1   Department of Hematology, Leiden University Medical Center, The Netherlands
,
Douwe E. Atsma
2   Department, of Cardiology, Leiden University Medical Center, The Netherlands
,
Pranobe V. Oemrawsingh
2   Department, of Cardiology, Leiden University Medical Center, The Netherlands
,
Jeroen Eikenboom
1   Department of Hematology, Leiden University Medical Center, The Netherlands
,
Felix J. M. Van der Meer
1   Department of Hematology, Leiden University Medical Center, The Netherlands
› Author Affiliations
Further Information

Publication History

Received 11 March 2004

Accepted after revision 04 June 2004

Publication Date:
15 December 2017 (online)

    Permissions and Reprints

 

 

  • References

  • 1 MacKinlay N, Taper J, Renisson F. et al. Cardiac surgery and catherization in patients with haemophilia. Haemophilia 2000; 06: 84-88.
    PubMedGoogle Scholar
  • 2 Hough RE, Hampton KH, Preston FE. et al. Recombinant VIIa concentrate in the management of bleeding following prothrombin complex-related myocardial infarction in patients with hemophilia and inhibitors. British J. Haematol 2000; 111: 974-979.
    PubMedGoogle Scholar
  • 3 Kohler M. Thrombogenicity of Prothrombin Complex Concentrates. Thromb Res 1999; 95: S13-S17.
    CrossrefPubMedGoogle Scholar
  • 4 Ehrlich HJ, Henzl MJ, Gomperts ED. Safety of factor VIII bypass activity (FEIBA®): 10-year compilation of thrombotic adverse events. Haemophilia 2002; 08: 83-90.
    CrossrefPubMedGoogle Scholar
  • 5 Peerlinck K, Vermylen J. Acute myocardial infarction following administration of recombinant activated factor VII (Novo seven) in a patient with haemophilia A and inhibitor (letter). Thromb Haemost 1999; 82: 1775-1776.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 6 Roberts HR. Clinical experience with activated recombinant factor VII: focus on safety aspects. Blood Coag. Fibrinol 1998; 09 (Suppl. 01) 119-120.
    CrossrefPubMedGoogle Scholar
  • 7 Lickfett L, Hagendorff A, Jung W. Akuter hinterwandinfarkt nach Faktor-VIII-Konzentrat bei schwerer Hamophilie A. Dtsch med Wschr 1998; 123: 658-662.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 8 Kopitsky RG, Geltman EM. Unstable angina associated with factor VIII concentrate therapy for haemophilia A. Ann Int Med 1986; 105 (02) 215-216.
    CrossrefPubMedGoogle Scholar
  • 9 Scharrer I. Experience with Kogenate® Bayer in surgical procedures. Haemophilia 2002; 08 (Suppl. 02) 15-18.
    CrossrefPubMedGoogle Scholar
  • 10 Rosendaal FR, Briët E, Stibbe J. et al. Haemophilia protects against ischaemic heart disease: a study of risk factors. Br J Haematol 1990; 75: 525-530.
    CrossrefPubMedGoogle Scholar
  • 11 Folsom AR, Rosamond WD, Shahar E. et al. Prospective study of markers of haemostatic function with risk of ischaemic stroke. Circulation 1999; 100: 736-742.
    CrossrefPubMedGoogle Scholar
  • 12 Kamphuisen PW, Eikenboom HCJ, Bertina RM. Elevated Factor VIII Levels and the Risk of Thrombosis. Arterioscler Thromb Vasc Biol 2001; 21: 731-738.
    CrossrefPubMedGoogle Scholar